Anidulafungin
Also known as: Anidulafungin sodium, Cancidas, Ecalta, Eraxis, FK463, LY303366, VER-002
Source Anidulafungin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Anidulafungin is a semisynthetic cyclic lipopeptide antifungal used intravenously for invasive candidiasis and other serious fungal infections.
Mechanism of Action
Inhibits fungal 1,3‑β‑D‑glucan synthase, disrupting cell‑wall synthesis
Routes of Administration
Goals & Uses
- Treatment of invasive candidiasis (intra-abdominal, peritonitis)Antifungal TherapyHigh
- Invasive candidiasis treatmentAntifungalHigh
- Empirical antifungal therapy in ICUAntifungal TherapyModerate
- Treatment of esophageal candidiasisAntifungal TherapyHigh
- Candida esophagitisAntifungalHigh
- Treatment of candidemiaAntifungal TherapyHigh
- Prophylaxis in high-risk patientsAntifungal ProphylaxisLow
Contraindications
- Hypersensitivity to polysorbate 80 (excipient)Excipient AllergyHigh
- Hypersensitivity to anidulafungin or any component of the formulationAllergyHigh
- Hypersensitivity to anidulafungin or other echinocandinsAllergyHigh
Adverse Effects
- Elevated liver enzymes (AST/ALT)HepatotoxicityCommon
- Elevated hepatic transaminases (ALT, AST)HepaticUncommon
- HypokalemiaElectrolyteRare
- Hepatic failureHepatotoxicityRare
- Infusion‑related reactions (flushing, rash, dyspnea)Infusion ReactionCommon
- Infusion-related reactions (flushing, hypotension, rash)Infusion ReactionUncommon
- Nausea/vomiting/diarrheaGastrointestinalCommon
- Deep vein thrombosis / phlebitisVascularUncommon
Drug Interactions
- Cytochrome P450 substratesLow
- CyclosporineLow
- VoriconazoleLow
- Concurrent hepatotoxic drugsModerate
- TacrolimusLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatric patients <3 monthsAgeRelative
- Pregnancy (Category C/unknown risk)PregnancyRelative
- BreastfeedingReproductiveRelative
- Elevated liver enzymes at baselineHepatic ImpairmentRelative
Regulatory Status
- European UnionApprovedApproved: invasive candidiasis, candidemia, candida esophagitisEMA approval; same indications as US
- United StatesApprovedApproved: invasive candidiasis, candidemia, candida esophagitisFDA approval 2001; marketed as Cancidas
- United KingdomApprovedApproved: Invasive candidiasis in adult non-neutropenic patientsApproved by MHRA (retained from EU approval); marketed as Ecalta
FDA‑approved (2001) as Cancidas for invasive candidiasis, candida esophagitis, and candidemia; EMA approved for similar indications.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Anidulafungin?
Anidulafungin is a semisynthetic cyclic lipopeptide antifungal used intravenously for invasive candidiasis and other serious fungal infections.
What is Anidulafungin used for?
Anidulafungin is educationally associated with: Treatment of invasive candidiasis (intra-abdominal, peritonitis), Invasive candidiasis treatment, Empirical antifungal therapy in ICU, Treatment of esophageal candidiasis, Candida esophagitis, Treatment of candidemia, Prophylaxis in high-risk patients. Educational only — not medical advice.
How is Anidulafungin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Anidulafungin?
Reported adverse effects include: Elevated liver enzymes (AST/ALT), Elevated hepatic transaminases (ALT, AST), Hypokalemia, Hepatic failure, Infusion‑related reactions (flushing, rash, dyspnea), Infusion-related reactions (flushing, hypotension, rash), Nausea/vomiting/diarrhea, Deep vein thrombosis / phlebitis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Anidulafungin?
Recorded contraindications: Hypersensitivity to polysorbate 80 (excipient), Hypersensitivity to anidulafungin or any component of the formulation, Hypersensitivity to anidulafungin or other echinocandins. Consult a qualified clinician before use.